收藏切换
Cost-effectiveness analysis of five hepatoprotective drugs in the treatment of drug-induced liver injury
收藏切换
Fanli JIANG, Yongjun LIU*, Yu QIU, Nannan LENG
World Clinical Drug | 2023, 44(8) : 832 - 840
Less
收藏切换
World Clinical Drug | 2023, 44(8): 832-840
• Article •
Cost-effectiveness analysis of five hepatoprotective drugs in the treatment of drug-induced liver injury
Full
Fanli JIANG, Yongjun LIU*, Yu QIU, Nannan LENG
Affiliations
  • School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 210000, Jiangsu Province, China
Published: 2023-08-10 doi: 10.13683/j.wph.2023.08.011
Outline
收藏切换
Objective

To conduct pharmacoeconomic analysis of 5 liver protective drug injections commonly used in clinic.

Methods

From the perspective of China's health system, Markov model was constructed according to the characteristics of drug-induced liver injury disease. The cost-effectiveness of 5 hepatoprotective drugs, including compound glycyrrhizin glucoside, polyene phosphatidyl choline, magnesium isoglycyrrhizinate, diammonium glycyrrhizinate and reduced glutathione were analyzed, and sensitivity analysis was performed to verify the robustness of the results.

Results

For patients with drug-induced liver injury, diammonium glycyrrhizinate, polyene phosphatidyl choline and reduced glutathione are the absolute inferior treatment regimen compared with compound glycyrrhizin, while magnesium isoglycyrrhizinate is more effective and higher cost than compound glycyrrhizin, and its incremental cost effect ratio incremental cost effectiveness ratio=3 500.57/quality adjusted life year is far less than the threshold value (3 times China's GDP per capita), which is the optimal treatment. The sensitivity analysis results were consistent with the basic analysis results, and all parameters changes did not change the model results.

Conclusion

Magnesium isoglycyrrhizinate is the most economical treatment plan, it is suggested to use magnesium isoglycyrrhizinate in clinical hepatoprotective treatment, in order to improve the overall social benefit and promote the rational allocation of medical resources.

hepatoprotective drugs  /  drug-induced liver injury  /  markov model  /  cost-effectiveness analysis
蒋范黎, 刘永军, 邱玉, 冷楠楠. 五种保肝药物治疗药物性肝损伤的成本-效果分析. 世界临床药物, 2023 , 44 (8) : 832 -840 . DOI: 10.13683/j.wph.2023.08.011
Fanli JIANG, Yongjun LIU, Yu QIU, Nannan LENG. Cost-effectiveness analysis of five hepatoprotective drugs in the treatment of drug-induced liver injury[J]. World Clinical Drug, 2023 , 44 (8) : 832 -840 . DOI: 10.13683/j.wph.2023.08.011
Year 2023 volume 44 Issue 8
5
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.08.011
  • Receive Date:2023-01-16
  • Online Date:2026-11-18
  • Published:2023-08-10
Article Data
Affiliations
History
  • Received:2023-01-16
Affiliations
    School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 210000, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.08.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT